SCHEMBL24007484

SCHEMBL24007484

CC(=O)N1CC2(CC(C(C)(C)C)C2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
EPHX2 P34913 2/20 0.40
KDM4E B2RXH2 1/20 0.33
KDM1A O60341 1/20 0.33
CHRNB2 P17787 2/20 0.32
CHRNA3 P32297 2/20 0.32
CHRNA4 P43681 2/20 0.32
CHRNB3 Q05901 1/20 0.32
CHRNA6 Q15825 1/20 0.32
CYP2D6 P10635 2/20 0.32
KCNH2 Q12809 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
CHRNB4 P30926 1/20 0.31
CYP1A2 P05177 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
CD274 Q9NZQ7 2/20 0.31
PDCD1LG2 Q9BQ51 1/20 0.31
PDCD1 Q15116 1/20 0.31
USP2 O75604 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29324699 0.81 EPHX2 (0.45) SMN1; SMN2EPHX2KDM4ECYP2D6CYP1A2
SCHEMBL25745691 0.80
SCHEMBL26738602 0.78 EPHX2 (0.42) SMN1; SMN2EPHX2USP2HPGD
SCHEMBL16075008 0.78 BTK (0.36) CYP2D6KCNH2HRH3
SCHEMBL25677360 0.77 SMN1; SMN2 (0.48) SMN1; SMN2EPHX2KDM4EKDM1ACHRNB2
SCHEMBL16074990 0.77 BTK (0.32)
SCHEMBL15472834 0.77 BTK (0.39)
SCHEMBL25824930 0.77 HSD11B1 (0.49) SMN1; SMN2CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL23992147 0.76 SMN1; SMN2 (0.40) SMN1; SMN2EPHX2KDM4EKDM1ACD274
SCHEMBL25543697 0.76 SMN1; SMN2 (0.40) SMN1; SMN2KDM4EKDM1ALOXL2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 US disclosed
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 US disclosed
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE HALIA THERAPEUTICS INC (US) 2023-06-15 US disclosed
WO-2021226261-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE LRRK2, SNCA, PRKAR2B SMN1; SMN2 536/4885EPHX2 4094/4885KDM4E 1686/4885
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B SMN1; SMN2 4718/4885EPHX2 4140/4885KDM4E 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.